spacer
home > ebr > autumn 2017 > eu impact
PUBLICATIONS
European Biopharmaceutical Review

EU Impact

25 May 2018 is an important date for pharmaceutical companies, CROs, software vendors and others supporting drug development, as this is when the new EU General Data Protection Regulation (GDPR) – what the EU calls “the most important change in data privacy regulation in 20 years” – comes into effect (1).

The new rules replace the 1995 Data Protection Directive 95/46/EC and are meant to harmonise data privacy laws across Europe, as well as “to protect and empower all EU citizens’ data privacy”. The GDPR will have a significant impact on how patient data are handled as it changes the way organisations approach information security.

When GDPR comes into effect, national governments will not be required to pass enabling legislation. The regulation will be applicable immediately, and serious violations may result in fines of €20 million or 4% of the organisation's worldwide revenues.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Jon Weisberg, Industry Advisor for EBR, heads public relations and communications for SAFE-BioPharma Association. He provides comprehensive editorial and consulting services to life sciences organisations.
spacer
Jon Weisberg
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Datwyler celebrates official opening of its new production plant with First Line standard in Middletown, Del

• The new facility in Middletown, Del., is Datwyler’s third facility with First Line standard which will be catering to the markets in North and South America • Approximately 120 jobs will be created, with the majority staffed from the local community • With the Middletown facility, Datwyler will be able to increase its global First Line production by 50 percent by 2020 • First Line is specially designed to manufacture biotech and pharmaceutical elastomer components in a fully integrated good manufacturing practice (GMP) environment
More info >>

White Papers

Biosimilars In Emerging Markets: Is It A Level Playing Field?

PRA Health Sciences (PRA)

Governments, healthcare payers, and social and health reforms, combined with the increased incidence of conditions such as cancer and diabetes are paving the way for increased uptake of biologic medicines in emerging markets. However, expensive biologic medicines can be prohibitive to many patients, creating a high level of unmet clinical need. At its best, the global expansion of biosimilars can mean a robust and steady supply of existing and new drugs reaching far-flung patient populations, but localized biosimilar drug developments, especially in China and India, combined with a lack of robust pharmacovigilance systems, threaten to derail the industry by putting patient health at risk.
More info >>

 
Industry Events

CPhI & P-MEC India 2018

12-14 December 2018, India Expo Mart, New Delhi, India

CPhI & P-MEC India (December 12-14, 2018) – organised by UBM (part of Informa PLC) – announces that the 12th edition of Asia’s largest Pharma exhibition is moving to the India Expo Mart, New Delhi. The new venue will see the exhibition now hosted in a single venue, bringing it closer to the Indian regulatory and legislative capital. New Delhi is also the country’s main international transport hub and will encourage an increased international attendance. In total, more than 50,000 people from 122 countries are expected, along with nearly 1,500 exhibitors.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement